The combination of minocycline and fluconazole causes synergistic growth inhibition against Candida albicans: An in vitro interaction of antifungal and antibacterial agents

FEMS Yeast Research

Volumn 10, Issue 7, 2010, Pages 885-893

  Shi, Wenna ^a   Chen, Zuozhong ^b   Chen, Xu ^a   Cao, Lili ^c   Liu, Ping ^a   Sun, Shujuan ^c  

^a SHANDONG UNIVERSITY   (China)

^b ZIBO CENTRAL HOSPITAL   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Biofilm; Calcium balance; Candida albicans resistance; Drug combination; Fluconazole accumulation

Indexed keywords

CALCIUM; FLUCONAZOLE; MINOCYCLINE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CALCIUM BALANCE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CANDIDA ALBICANS; DRUG EFFECT; DRUG MECHANISM; GROWTH INHIBITION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SPECTROPHOTOMETRY;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; DRUG SYNERGISM; FLUCONAZOLE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

CANDIDA ALBICANS; FUNGI;

EID: 78650424102     PISSN: 15671356     EISSN: 15671364     Source Type: Journal    
DOI: 10.1111/j.1567-1364.2010.00664.x     Document Type: Article

References (38)

1. Adam G & Duncan H (2001) Development of a sensitive and rapid method for the measurement of total microbial activity using fluorescein diacetate (FDA) in a range of soils. Soil Biol Biochem 33: 943-951.
2. Afeltra J, Vitale RG, Mouton JW & Verweij PE (2004) Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole. Antimicrob Agents Ch 48: 1335-1343.
3. Anderl JN, Franklin MJ & Stewart PS (2000) Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Ch 44: 1818-1824.
4. Andes D, Nett J, Oschel P, Albrecht R, Marchillo K & Pitula A (2004) Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect Immun 72: 6023-6031.
5. Bachmann SP, Ramage G, VandeWalle K, Patterson TF, Wickes BL & López-Ribot JL (2003) Antifungal combinations against Candida albicans biofilms in vitro. Antimicrob Agents Ch 47: 3657-3659.
6. Baumgartner C, Freydiere A & Gile Y (1996) Direct identification and recognition of yeast species from clinical material by using albicans ID and CHROMagar Candida plates. J Clin Microbiol 34: 454-456.
7. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T & Ghannoum MA (2001) Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 183: 5385-5394.
8. Corner BE & Magee PT (1997) Candida pathogenesis: unravelling the threads of infection. Curr Biol 7: R691-R694.
9. Cutler JE (1991) Putative virulence factors of Candida albicans. Annu Rev Microbiol 45: 187-218.
10. Donlan RM & Costerton JW (2002) Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15: 167-193.
11. Fricker-Hidalgo H, Vandapel O, Duchesne MA et al. (1996) Comparison of the new API Candida system to the ID 32C system for the identification of clinically important yeast species. J Clin Microbiol 34: 1846-1848.
12. Honraet K, Goetghebeur E & Nelis HJ (2005) Comparison of three assays for the quantification of Candida biomass in suspension and CDC reactor grown biofilms. J Microbiol Meth 63: 287-295.
13. Kohli A, Smriti NFN, Mukhopadhyay K, Rattan A & Prasad R (2002) In vitro low-level resistance to azoles in Candida albicans is associated with changes in membrane lipid fluidity and asymmetry. Antimicrob Agents Ch 46: 1046-1052.
14. Lew MA, Beckett KM & Levin MJ (1997) Antifungal activity of four tetracycline analogues against Candida albicans in vitro: potentiation by amphotericin B. J Infect Dis 136: 263-270.
15. Maesaki S, Marichal P, Vanden Bossche H, Sanglard D & Kohno S (1999) Rhodamine 6G efflux for the detection of CDR1-overexpressing azole-resistant Candida albicans strains. J Antimicrob Chemoth 44: 27-31.
16. Morschhäuser J (2010) Regulation of multidrug resistance in pathogenic fungi. Fungal Genet Biol 47: 94-106.
17. Mukherjee PK, Sheehan DJ, Hitchcock CA et al. (2005) Combination treatment of invasive fungal infections. Clin Microbiol Rev 18: 163-194.
18. National Committee for Clinical Laboratory Standards (2002) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard. NCCLS Document M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
19. Odds FC (1994) Pathogenesis of Candida infections. J Am Acad Dermatol 31: S2-S5.
20. Oliveira LF, Jorge AOC & Santos SSF (2006) In vitro minocycline activity on superinfecting microorganisms isolated from chronic periodontitis patients. Braz Oral Res 20: 202-206.
21. Onyewu C, Blankenship JR, Del Poeta M & Heitman J (2003) Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. Antimicrob Agents Ch 47: 956-964.
22. Peeters E, Nelis HJ & Coenye T (2008) Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates. J Microbiol Meth 72: 157-165.
23. Pfaller MA & Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20: 133-163.
24. Pfaller MA, Houston A & Coffman S (1996) Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrata. J Clin Microbiol 34: 58-61.
25. Prieto B, Silva B & Lantes O (2004) Biofilm quantification of stone surfaces: comparison of various methods. Sci Total Environ 333: 1-7.
26. Raad I, Darouiche R, Hachem R, Sacilowski M & Bodey GP (1995) Antibiotics and prevention of microbial colonization of catheters. Antimicrob Agents Ch 39: 2397-2400.
27. Rogers TR (2002) Antifungal drug resistance: does it matter? Int J Infect Dis 6: s47-s53.
28. Sanglard D (2003) Resistance and tolerance mechanisms to antifungal drugs in fungal pathogens. Mycologist 17: 74-78.
29. Schierholz JM, Pulverer G, Bach A & Wachol-Drebeck Z (1999) In vitro activity of rifampin-minocyclin coating to Candida albicans. Crit Care Med 27: 1691-1693.
30. Sherertz RJ, Boger MS, Collins CA, Mason L & Raad II (2006) Comparative in vitro efficacies of various catheter lock solutions. Antimicrob Agents Ch 50: 1865-1868.
31. Stewart PS & Costerton JW (2001) Antibiotic resistance of bacteria in biofilms. Lancet 358: 135-138.
32. Suci PA, Mittelman MW, Yu FP & Geesey GG (1994) Investigation of ciprofloxacin penetration into Pseudomonas aeruginosa biofilms. Antimicrob Agents Ch 38: 125-133.
33. Sun S, Li Y, Guo Q, Shi C, Yu J & Ma L (2008) In vitro interactions between tacrolimus and azoles against albicans determined by different methods. Antimicrob Agents Ch 52: 409-417.
34. Taylor JP, Wilson B, Mills MS & Burns RG (2001) Comparison of microbial numbers and enzymatic activities in surface soils and subsoil using various techniques. Soil Biol Biochem 34: 387-401.
35. Waterworth PM (1974) The effect of minocycline on Candida albicans. J Clin Pathol 27: 269-272.
36. Wilson M, O'Connor B & Newman HN (1991) Isolation and identification of bacteria from subgingival plaque, with low susceptibility to minocycline. J Periodontol 8: 71-78.
37. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP & Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39: 309-317.
38. Zheng Z & Stewart PS (2002) Penetration of rifampin through Staphylococcus epidermidis biofilms. Antimicrob Agents Ch 46: 900-903.